Peer-reviewedCC BY-NC-NDInternal Medicine
A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment
Abstract
We report a case of unresectable hepatocellular carcinoma (HCC) that responded to durvalumab plus tremelimumab after disease progression during atezolizumab monotherapy and intolerance to lenvatinib. A 74-year-old man with a Child-Pugh A liver function developed multifocal HCC that was refractory to prior therapies. Tumor markers transiently increased after durvalumab plus tremelimumab initiation, followed by normalization and radiological tumor shrinkage without any new lesions. This response may be associated with lenvatinib-mediated modulation of the tumor microenvironment and/or immune activation induced by CTLA-4 blockade.
Related
- Immune-mediated Myocarditis after Durvalumab/tremelimumab Treatment for Unresectable Hepatocellular Carcinoma
- Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma.
- Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
- An Effective Case of Radiofrequency Ablation with the Combination of Durvalumab and Tremelimumab Treatment for Hepatocellular Carcinoma
- Survival outcomes of spleen-strengthening and dampness-eliminating traditional Chinese medicine granules combined with lenvatinib for unresectable hepatocellular carcinoma: a large-sample retrospective study based on electronic medical records
BibTeX
@article{sueda2026case,
title = {{A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment}},
author = {Saki Sueda and Tomokazu Kawaoka and Yasutoshi Fujii and Hatsue Fujino and Atsushi Ono and Eisuke Murakami and C. Nelson Hayes and Daiki Miki and Masataka Tsuge and Shiro Oka},
journal = {Internal Medicine},
year = {2026},
month = aug,
doi = {10.2169/internalmedicine.7369-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7369-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment
AU - Saki Sueda
AU - Tomokazu Kawaoka
AU - Yasutoshi Fujii
AU - Hatsue Fujino
AU - Atsushi Ono
AU - Eisuke Murakami
AU - C. Nelson Hayes
AU - Daiki Miki
AU - Masataka Tsuge
AU - Shiro Oka
PY - 2026
DA - 2026/08/19
JO - Internal Medicine
DO - 10.2169/internalmedicine.7369-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7369-26/_article
AB - We report a case of unresectable hepatocellular carcinoma (HCC) that responded to durvalumab plus tremelimumab after disease progression during atezolizumab monotherapy and intolerance to lenvatinib. A 74-year-old man with a Child-Pugh A liver function developed multifocal HCC that was refractory to prior therapies. Tumor markers transiently increased after durvalumab plus tremelimumab initiation, followed by normalization and radiological tumor shrinkage without any new lesions. This response may be associated with lenvatinib-mediated modulation of the tumor microenvironment and/or immune activation induced by CTLA-4 blockade.
SN - 1349-7235
SN - 0918-2918
ER -